Epival Contraindications

Divalproex sodium/Valproate/Valproic Acid should not be administered to patients with hepatic disease or significant hepatic dysfunction (see Hepatotoxicity under Precautions).
Divalproex sodium/Valproate/Valproic Acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g. Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder (see Hepatotoxicity under Precautions).
Divalproex sodium/Valproate/Valproic Acid is contraindicated in patients with known systemic primary carnitine deficiency with uncorrected hypocarnitinemia (see Patients at risk of hypocarnitinemia under Precautions).
Divalproex sodium/Valproate/Valproic Acid is contraindicated in patients with known hypersensitivity to the drug (see Multi-Organ Hypersensitivity Reactions under Precautions).
Divalproex sodium/Valproate/Valproic Acid is contraindicated in patients with known urea cycle disorders (see Hyperammonemia: Urea Cycle Disorders under Precautions).
Divalproex sodium/Valproate/Valproic Acid is contraindicated in the following situation: Treatment of epilepsy: in pregnancy unless there is no suitable alternative treatment (see Warnings and Use in Pregnancy & Lactation); in women of childbearing potential, unless the measures for prevention of pregnancy as mentioned in Warnings and Use in Pregnancy & Lactation are met.
Treatment of mania and prophylaxis of migraine attacks: in pregnancy (see Warnings and Use in Pregnancy & Lactation); in women of childbearing potential, unless the measures for prevention of pregnancy as mentioned in Warnings and Use in Pregnancy & Lactation are met.
Divalproex sodium/Valproate/Valproic Acid is contraindicated in patients with porphyria.